ASCO 2024 Heme Malig WC

CME

Conference to Clinic: Hematologic Malignancies

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: July 02, 2024

Expiration: January 01, 2025

Shaji K. Kumar
Shaji K. Kumar, MD
Jeffrey P. Sharman
Jeffrey P. Sharman, MD
Eunice S. Wang
Eunice S. Wang, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Presurvey 1: At ASCO 2024, results from the phase III ASC4FIRST study of oral asciminib vs investigator-selected tyrosine kinase inhibitor (IS-TKI: imatinib, nilotinib, dasatinib, or bosutinib) for patients with newly diagnosed Ph-positive CML in chronic phase were presented. Which of the following results was demonstrated?

2.

Patient Case: Newly Diagnosed Multiple Myeloma



  • 76-yr-old male with history of type II diabetes and low back pain x10 yr after motor vehicle accident presents with increased fatigue

  • Exam shows: 

    • Anemia with Hgb 9.7 g/dL

    • Serum electrophoresis: M-spike: 4.2 g/dL, IF: IgG K

    • Bone marrow aspirate: 30% plasma cells

    • Cytogenetics (FISH): t(14;16); TP53 mutation

    • Low-dose whole-body CT: diffuse bone lesions, spine

    • Creatinine: creatinine clearance 30 mL/min; β2 microglobulin: 2.5 mg/L; albumin: 3.8 g/dL; LDH normal



Presurvey 2: Which of the following would you recommend for this patient based on the newest data from ASCO 2024?

3.

Presurvey 3: The phase III DREAMM-8 trial evaluating belantamab mafodotin + pom/dex vs bortezomib + pom/dex after ≥1 line of therapy (including lenalidomide) reported which of the following with belantamab mafodotin?

4.

Presurvey 4: In the phase III ECHELON-3 trial, which of the following best describes the patient population with R/R DLBCL that experienced an OS benefit with the addition of brentuximab vedotin to lenalidomide and rituximab?